Abstract 7570: Expanding digital access to cancer immunotherapy trials: Nationwide engagement and high match rates among 21,000 patients.

Abstract Clinical trials are essential to advancing cancer care and precision medicine. They provide access to innovative treatments and are fundamental to validating new therapies, generating evidence for regulatory approval and improved care. Yet participation remains limited - only 9% of U.S. patients report being invited to a clinical trial, and one in five adult cancer trials fail to finish due to low enrollment. Increasing patient and provider awareness and helping patients navigate their best options are key to closing this gap. To help address these barriers, the Cancer Research Institute (CRI) provides a free, online Clinical Trial Finder designed to connect patients with cancer immunotherapy trials. The tool uses a short survey to match users to open studies based on cancer type, location, and other eligibility criteria. Users can access the full portfolio of clinical trials sourced from the ClinicalTrials.gov and search by cancer type, drug type, trial phase, and sponsor. Additional one-on-one trial navigation support is available by phone or email. Over nine months, more than 21,300 individuals visited the CRI Clinical Trial Finder webpage (https://cri.careboxhealth.com/en-US/). Nearly all individuals who completed the survey did so online (95.6%, 3,651) rather than by phone or email (169, 4.4%). Survey completion rates were also higher for online users (2,510, 68.7%) versus phone or email (87, 5.1%). Among all individuals who completed the survey (n=2,597), 97.2% matched to at least one open clinical trial. This match rate is substantially higher than published reports and may reflect broad eligibility of cancer-type-agnostic and genomically-driven immunotherapy trials. Users came from 49 U.S. states and the District of Columbia, with the largest numbers in California (157), Texas (74), and Florida (74) (n=1,036 who provided location); there were no users in Wyoming. These data mirror general U.S. population distribution and demonstrate nation-wide reach. About one-third (1,210) of users reported a diagnosis of pancreatic, breast, or ovarian cancer. While breast cancer is the most commonly diagnosed cancer among women in the U.S., pancreatic and ovarian cancers are lower incidence and often detected in later stages, with fewer treatment options, making clinical trials particularly relevant for these patients. Individuals with sarcoma (118), kidney (66), skin (16), thyroid (8), or testicular (4) cancer had a 100% match rate. Melanoma had the lowest (87.3%, 48). Our findings demonstrate how online, patient-friendly tools supplemented with personalized navigational support can help bridge the gap between patients and cancer research. By lowering barriers to access and empowering patients, digital trial-matching services can help advance clinical trial participation and make more life-saving immunotherapies available to more people. AI was used to review abstract text. Citation Format: Cynthia L. Neben, Wendy Weise, Samik Upadhaya, Alicia Y. Zhou, . Expanding digital access to cancer immunotherapy trials: Nationwide engagement and high match rates among 21,000 patients abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7570.